Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Resonance Speci.
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 18.38 | 13.46 | 10.14 | 15.34 | 16.36 | 17.30 | 18.06 | 18.24 | 24.20 | 21.27 | 21.53 | 22.96 | 24.48 |
| Expenses + | 16.58 | 11.87 | 9.22 | 14.02 | 15.31 | 15.22 | 15.71 | 16.35 | 19.95 | 18.72 | 19.17 | 19.51 | 18.84 |
| Operating Profit | 1.80 | 1.59 | 0.92 | 1.32 | 1.05 | 2.08 | 2.35 | 1.89 | 4.25 | 2.55 | 2.36 | 3.45 | 5.64 |
| OPM % | 9.79% | 11.81% | 9.07% | 8.60% | 6.42% | 12.02% | 13.01% | 10.36% | 17.56% | 11.99% | 10.96% | 15.03% | 23.04% |
| Other Income + | 0.18 | 0.14 | 0.25 | 0.25 | 0.29 | -0.64 | 0.45 | 0.30 | 0.07 | 0.23 | 0.35 | 0.32 | 0.74 |
| Interest | 0.04 | 0.07 | 0.09 | 0.11 | 0.12 | 0.10 | 0.10 | 0.08 | 0.03 | 0.08 | 0.06 | 0.05 | 0.05 |
| Depreciation | 0.39 | 0.35 | 0.36 | 0.38 | 0.37 | 0.48 | 0.49 | 0.48 | 0.11 | 0.33 | 0.33 | 0.34 | 0.34 |
| Profit before tax | 1.55 | 1.31 | 0.72 | 1.08 | 0.85 | 0.86 | 2.21 | 1.63 | 4.18 | 2.37 | 2.32 | 3.38 | 5.99 |
| Tax % | 20.65% | 33.59% | 36.11% | 11.11% | 21.18% | 31.40% | 18.10% | 31.90% | 26.79% | 31.22% | 28.88% | 26.04% | 23.37% |
| Net Profit + | 1.24 | 0.87 | 0.46 | 0.96 | 0.67 | 0.59 | 1.81 | 1.12 | 3.06 | 1.63 | 1.66 | 2.51 | 4.60 |
| EPS in Rs | 1.07 | 0.75 | 0.40 | 0.83 | 0.58 | 0.51 | 1.57 | 0.97 | 2.65 | 1.41 | 1.44 | 2.17 | 3.98 |
Financials of Resonance Speci.
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 38 | 39 | 34 | 36 | 41 | 56 | 70 | 76 | 58 | 55 | 78 | 90 |
| Expenses + | 37 | 36 | 32 | 35 | 37 | 48 | 56 | 59 | 51 | 50 | 67 | 76 |
| Operating Profit | 1 | 3 | 2 | 1 | 5 | 8 | 14 | 17 | 7 | 5 | 11 | 14 |
| OPM % | 3% | 8% | 6% | 2% | 12% | 14% | 20% | 22% | 12% | 9% | 14% | 16% |
| Other Income + | 2 | 0 | 1 | 1 | 1 | 0 | 2 | 1 | 2 | 1 | 0 | 2 |
| Interest | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 |
| Profit before tax | 1 | 2 | 1 | 0 | 5 | 7 | 15 | 16 | 7 | 4 | 9 | 14 |
| Tax % | 7% | 28% | 26% | 2,700% | 33% | 20% | 28% | 24% | 27% | 25% | 26% | 26% |
| Net Profit + | 1 | 1 | 1 | -1 | 3 | 6 | 11 | 12 | 5 | 3 | 7 | 10 |
| EPS in Rs | 1.11 | 1.03 | 0.89 | -0.67 | 2.77 | 4.77 | 9.11 | 10.71 | 4.33 | 2.57 | 5.69 | 9.01 |
| Dividend Payout % | 45% | 0% | 0% | 0% | 0% | 21% | 11% | 9% | 23% | 0% | 18% | 11% |
Financials of Resonance Speci.
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 10 | 11 | 12 | 12 | 15 | 19 | 29 | 40 | 44 | 46 | 52 | 62 |
| Borrowings + | 3 | 2 | 4 | 3 | 0 | 0 | 1 | 0 | 2 | 4 | 3 | 2 |
| Other Liabilities + | 10 | 8 | 12 | 10 | 12 | 11 | 13 | 5 | 8 | 12 | 8 | 17 |
| Total Liabilities | 35 | 32 | 40 | 37 | 38 | 41 | 55 | 57 | 66 | 74 | 76 | 92 |
| Fixed Assets + | 14 | 14 | 15 | 15 | 14 | 14 | 16 | 14 | 20 | 23 | 21 | 21 |
| CWIP | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 4 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 12 |
| Other Assets + | 20 | 18 | 25 | 22 | 23 | 25 | 38 | 42 | 45 | 48 | 54 | 57 |
| Total Assets | 35 | 32 | 40 | 37 | 38 | 41 | 55 | 57 | 66 | 74 | 76 | 92 |
Financials of Resonance Speci.
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1 | 3 | 1 | 2 | 5 | 1 | 4 | 13 | -8 | 4 | -3 | 17 |
| Cash from Investing Activity + | -0 | -1 | -3 | -1 | -0 | -2 | -1 | -9 | 3 | -7 | 2 | -15 |
| Cash from Financing Activity + | -2 | -2 | 2 | -1 | -4 | 1 | 0 | -2 | 1 | 0 | -1 | -2 |
| Net Cash Flow | -1 | 0 | -0 | 0 | 1 | 1 | 3 | 3 | -4 | -2 | -2 | -0 |
| Free Cash Flow | 1 | 2 | -2 | 1 | 5 | -1 | 3 | 13 | -16 | -0 | -4 | 14 |
| CFO/OP | 103% | 122% | 28% | 362% | 107% | 47% | 61% | 110% | -93% | 117% | -5% | 143% |
Financials of Resonance Speci.
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 99 | 66 | 80 | 68 | 67 | 40 | 49 | 40 | 78 | 89 | 105 | 56 |
| Inventory Days | 134 | 159 | 397 | 212 | 180 | 232 | 236 | 176 | 646 | 341 | 316 | 317 |
| Days Payable | 116 | 108 | 262 | 127 | 139 | 114 | 121 | 17 | 138 | 134 | 65 | 112 |
| Cash Conversion Cycle | 117 | 117 | 215 | 152 | 108 | 158 | 164 | 198 | 587 | 295 | 356 | 261 |
| Working Capital Days | 71 | 74 | 85 | 80 | 93 | 82 | 99 | 143 | 212 | 221 | 206 | 202 |
| ROCE % | 4% | 9% | 7% | 2% | 20% | 31% | 41% | 35% | 13% | 7% | 15% | 20% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…